{"id":"bb2121","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"bb2121 involves engineering a patient's T cells to express a CAR that targets B-cell maturation antigen (BCMA), a surface protein highly expressed on multiple myeloma cells. Once infused back into the patient, these CAR-T cells expand and attack myeloma cells. This approach harnesses the immune system's ability to specifically recognize and eliminate cancer cells.","oneSentence":"bb2121 is a chimeric antigen receptor (CAR) T-cell therapy that redirects a patient's own T cells to recognize and kill multiple myeloma cells expressing BCMA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:40.077Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05032820","phase":"PHASE2","title":"Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2022-01-05","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT06045806","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2023-10-16","conditions":"Multiple Myeloma","enrollment":79},{"nctId":"NCT03601078","phase":"PHASE2","title":"An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-12-13","conditions":"Multiple Myeloma","enrollment":312},{"nctId":"NCT05393804","phase":"PHASE2","title":"A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-05-20","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT04771078","phase":"","title":"Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release","status":"AVAILABLE","sponsor":"Celgene","startDate":"","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT04855136","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma","status":"TERMINATED","sponsor":"Celgene","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":21},{"nctId":"NCT03361748","phase":"PHASE2","title":"Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-12-13","conditions":"Multiple Myeloma","enrollment":149},{"nctId":"NCT04196491","phase":"PHASE1","title":"A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)","status":"COMPLETED","sponsor":"Celgene","startDate":"2020-05-27","conditions":"Multiple Myeloma","enrollment":13},{"nctId":"NCT02658929","phase":"PHASE1","title":"Study of bb2121 in Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-22","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT03651128","phase":"PHASE3","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":381},{"nctId":"NCT02786511","phase":"","title":"Longterm Follow-up of Subjects Treated With bb2121","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-04-28","conditions":"Multiple Myeloma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ide-cel","BMS-986395"],"phase":"phase_3","status":"active","brandName":"bb2121","genericName":"bb2121","companyName":"Celgene","companyId":"celgene","modality":"Biologic","firstApprovalDate":"","aiSummary":"bb2121 is a chimeric antigen receptor (CAR) T-cell therapy that redirects a patient's own T cells to recognize and kill multiple myeloma cells expressing BCMA. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}